share_log

Femasys | 10-K/A: Annual report (Amendment)

SEC announcement ·  Apr 26 17:19
Summary by Moomoo AI
Femasys Inc., a medical technology company, has filed an amended annual report for the fiscal year ended December 31, 2023. The amendment includes previously omitted information required by Items 10 through 14 of Part III of Form 10-K, which pertains to directors, executive officers, corporate governance, executive compensation, and other related matters. The amendment also updates the exhibit list in Item 15 of Part IV. This filing does not reflect any new financial statements or modify disclosures affected by subsequent events. The company's Board of Directors consists of five members, with staggered three-year terms. The Board includes individuals with extensive experience in the life sciences, medical device industry, and financial technology. Femasys has also disclosed the compensation of its directors and executive officers...Show More
Femasys Inc., a medical technology company, has filed an amended annual report for the fiscal year ended December 31, 2023. The amendment includes previously omitted information required by Items 10 through 14 of Part III of Form 10-K, which pertains to directors, executive officers, corporate governance, executive compensation, and other related matters. The amendment also updates the exhibit list in Item 15 of Part IV. This filing does not reflect any new financial statements or modify disclosures affected by subsequent events. The company's Board of Directors consists of five members, with staggered three-year terms. The Board includes individuals with extensive experience in the life sciences, medical device industry, and financial technology. Femasys has also disclosed the compensation of its directors and executive officers, including equity awards and severance arrangements. The company has adopted a clawback policy for executive compensation and maintains a 401(k) retirement savings plan for employees. As of April 25, 2024, Femasys has 22,220,718 shares of common stock outstanding. The company's audit committee oversees corporate accounting and financial reporting processes, and KPMG LLP serves as the independent registered public accounting firm. The report also includes information on beneficial ownership of common stock by certain stockholders, executive officers, and directors, as well as details on equity compensation plans and related person transactions.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more